Trial Profile

Phase 1 single and multiple ascending dose (SAD/MAD) study of long-acting PAS-nomacopan for Geographic Atrophy

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomacopan (Primary)
Indications Dry macular degeneration
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

19 Aug 2024 According to an Akari Therapeutics media release, company received positive and constructive pre-IND feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy and plan on filing an IND application in 2025.
22 Nov 2023 New trial record
16 Nov 2023 According to an Akari Therapeutics media release, the company expects to submit IND in 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com